Stock screener

KLRS

Conviction 32HealthcareScan · Thu, Jun 25, 2026
KLRS$4.32-1.93%
ResistanceSupportVol 14Insider buy
63 bars
5
Vol MA14 89.9K
Mar 26Apr 14May 1May 19Jun 8Jun 25
Kalaris Therapeutics, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.kalaristx.com
Price4.32
Change-1.93%
Gap-0.91%
Rel volume2.94×
Avg volume84.7K
Avg $ vol384.73K
SMA 204.52
SMA 505.08
SMA 2006.68
Price vs 50-15.10%
Price vs 200-35.39%
MA stackbearish
50/200 cross
Supertrenddown · 5.19
RSI (14)41
MACD hist0.04
MACD crossbull · 6d
Stoch %K / %D38 / 44
ADX (14)15
+DI / −DI17 / 19
RSI divergence
MACD divergence
ATR %+7.67%
ADR %6.71%
52w high10.98
52w low2.27
From 52w high-60.70%
Above 52w low+90.09%
New 52w highNo
SqueezeOff
Bollinger width27.47%
%B0.33
Donchian pos18.85%
Donchian high5.60
Donchian low4.02
AVWAP (52w high)7.25
vs AVWAP high-40.48%
AVWAP (52w low)6.00
vs AVWAP low-28.03%
OBV trendDown
Chaikin MF (20)-0.30
Today vs 20d2.94×
Avg vol (14d)89.89K
Avg vol (20d)84.7K
Avg $ vol (20d)384.73K
Market cap102.66M
RS 3m (vs SPY)-41.29%
RS 6m (vs SPY)-59.54%
RS line new highNo
Trend template3/8
Technical rank10.2
1 week-5.16%
1 month-17.18%
3 months-29.44%
6 months-57.11%
1 year+73.29%
YTD-48.01%
P/E-2.36
P/B1.50
P/S622.20
P/FCF-2.66
EPS-2.85
Div yield
ROE-63.36%
ROA-39.56%
Debt/Eq
Current12.19
EV/EBITDA-1.49
Gross margin
Net margin
Rev growth
EPS growth37.20%
Price target
Target upside
Analyst rating
Institutional
Ent. value68.24M
Revenue165K
Net income-10.86M
Gross profit
Free cash flow-38.57M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out23.79M
Employees20
ListedWed, Mar 19, 2025
Free float3.17M
Float %17.0%
Short interest801.52K
Days to cover10.3d
Short volume8.0%
Squeeze score80 / 100
Next earnings
EPS forecast
Last EPS vs est
Last surprise
Setup gradeD
Conviction32 / 100
Pattern quality
Tech rank10.2 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction
Pattern family
Resistance5.49
Support4.27
Days since event
Candle confirm
News sentiment

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in KLRS

All disclosures →
No recent disclosed trades by Congress in KLRS. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in KLRS · 10 buys

InsiderSideShares
AKKARAJU SRINIVAS
Director · Stock Option (Right to Buy) · 2026-06-03
Grant9K
Ferrara Napoleone
Director · Stock Option (Right to Buy) · 2026-06-03
Grant9K
Hallal David
Director · Stock Option (Right to Buy) · 2026-06-03
Grant9K
ADAMIS ANTHONY P
Director · Stock Option (Right to Buy) · 2026-06-03
Grant9K
Jovan-Embiricos Morana
Director · Stock Option (Right to Buy) · 2026-06-03
Grant9K
PATTERSON LEONE D
Director · Stock Option (Right to Buy) · 2026-06-03
Grant9K
Dybbs Michael
Director · Stock Option (Right to Buy) · 2026-06-03
Grant9K
AKKARAJU SRINIVAS
Director · Common Stock · 2026-05-20
Buy244.3K
AKKARAJU SRINIVAS
Director · Common Stock · 2026-05-20
Acquire14.94K
AKKARAJU SRINIVAS
Director · Common Stock · 2026-05-20
Acquire4.47K

SEC filings

EDGAR filings in KLRS · 1 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.